Chai Discovery, a biotech startup backed by OpenAI, has introduced Chai-2, a multimodal generative AI model that achieves fully de novo antibody design with a hit rate of approximately 16%, representing a 100-fold improvement over previous methods. Chai-2 can design, synthesize, and characterize antibodies in under two weeks, a process that traditionally takes months to years and requires substantial investment. The model has demonstrated success across 52 diverse targets with fewer than 20 AI-designed candidates per target, significantly accelerating and reducing the cost of drug discovery. Concurrently, researchers at Stanford University and the Chan Zuckerberg Biohub have developed a virtual lab composed of autonomous AI agents capable of designing hypotheses, debating ideas, and conducting biomedical experiments. This virtual lab has rapidly generated COVID-19 nanobody candidates within days, showcasing the potential for AI-driven continuous scientific discovery. These advancements highlight a shift toward AI-powered platforms that can expedite biomedical research and precision medicine development.